Currently, the only cure for severe ulcerative colitis is surgical removal of the affected colon. Overall, treatment for ulcerative colitis is focused on reducing symptoms and increasing the possibility of long-term remission.

Types of Treatments

There are a variety of treatments for ulcerative colitis. These treatments are described in more detail below.

  • Anti-inflammatory agents
  • Immunomodulator drugs
  • Immunotherapy
  • Anti-diarrheal drugs
  • Diet and nutrition therapy
  • Surgery

Anti-inflammatory drugs – Anti-inflammatory drugs are often the first-line treatment for ulcerative colitis. Anti-inflammatory drugs for the treatment of ulcerative colitis may be given by mouth, enema, or suppository.

Anti-inflammatory drugs used for the treatment of ulcerative colitis may include:

  • Baldalazide
  • Budesonide
  • Cololsalazine
  • Mesalamine
  • Prednisone
  • Sulfasalazine

Immunomodulator drugs –Immunomodulators reduce inflammation by decreasing the body’s immune defenses.

Immunomodulator drugs used for the treatment of ulcerative colitis may include:

  • Azathioprine
  • Cyclosporine
  • Mercaptopurine
  • Tofacitinib

Immunotherapy, also called biologics – Immunotherapy targets the immune system, or the body’s natural defenses, to reduce inflammation.

Immunotherapy drugs used for the treatment of ulcerative colitis may include:

  • Adalimumab
  • Golimumab
  • Infliximab
  • Vedolizumab

Anti-diarrheal drugs – Anti-diarrheal medications, such as loperamide, may be recommended to manage severe diarrhea associated with ulcerative colitis. Anti-diarrheal medications should be used with caution under the care of a doctor.

Pain medication – Acetaminophen may be recommended for mild-to-moderate pain associated with ulcerative colitis.

Antibiotics – Antibiotics may be given for ulcerative colitis to treat bacterial infections of the digestive tract.

Diet and nutrition therapy – Changes in diet may be necessary to help reduce and manage the symptoms of ulcerative colitis, such as:

  • Eating smaller meals more frequently
  • Drinking more liquids
  • Avoiding fizzy drinks, caffeinated beverages, alcohol, fried foods, high-fiber foods, high-fat foods, artificial food additives, dyes, and sweeteners, and lactose
  • Vitamins and other supplements may also be given to treat nutritional deficiencies often associated with ulcerative colitis.

Surgery – For some patients with severe ulcerative colitis, surgery may be necessary.

Types of surgery used for the treatment of ulcerative colitis may include:

Removal of the entire colon and rectum, which can cure ulcerative colitis.

Ileal pouch anal anastomosis – In this surgery, a pouch is made from the small intestine and used to replace the rectum. This allows for normal passage of waste and avoiding having a permanent opening into abdomen called a stoma.

Ileal stoma – When an ileal pouch cannot be done, a permanent opening in abdomen called a stoma will be created and covered with the placement of a stool collection bag.

Proctocolectomy – A proctocolectomy involves the removal of the entire colon and rectum. Next, a permanent opening in abdomen called a stoma is created. A stool collection bag is placed over the stoma.

A proctocolectomy can also be performed with an ileoanal reservoir, which connects a portion of small intestine to the anus to create a pouch to replace the rectum.

New and Experimental Therapies

New and experimental therapies for the treatment of ulcerative colitis include:

  • Etrolizumab
  • Filgotinib
  • Guselkumab
  • Mesenchymal stem cells
  • Mirikizumab
  • Ozanimod
  • Risankizumab
  • Tofactitinib
  • Upadactitinib
  • Ustekinumab

Long-Term Follow Up

Ongoing, long-term follow-up is an essential part of treatment for patients with ulcerative colitis to monitor the disease’s progression and the effectiveness of treatment.

Sources

This content was written by the MediFind Medical Team. Last updated: 6/9/2022

Medications for Ulcerative Colitis

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Ulcerative Colitis.

Found 26 Approved Drugs for Ulcerative Colitis

Infliximab

Brand Names
Zymfentra, Avsola, Inflectra, Remicade, Renflexis

Infliximab

Brand Names
Zymfentra, Avsola, Inflectra, Remicade, Renflexis
ZYMFENTRA is a tumor necrosis factor (TNF) blocker indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. ( 1 ) moderately to severely active Crohn’s disease following treatment with an infliximab products administered intraneously. ( 1 ) ZYMFENTRA is indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. moderately to severely active Crohn's disease following treatment with an infliximab product administered intravetnously.

Mesalamine

Brand Names
Pentasa, Canasa, Apriso, Lialda, sfRowasa Sulfite-Free, Rowasa

Mesalamine

Brand Names
Pentasa, Canasa, Apriso, Lialda, sfRowasa Sulfite-Free, Rowasa
Mesalamine delayed-release tablets are indicated for the: induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis. Pediatric use information is approved for Takeda Pharmaceuticals U.S.A., Inc.'s LIALDA (mesalamine) delayed-release tablets. However, due to Takeda Pharmaceuticals U.S.A., Inc.'s marketing exclusivity rights, this drug product is not labeled with that information. Mesalamine delayed-release tablets are an aminosalicylate indicated for the: induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis. ( 1 )

Entyvio

Generic Name
Vedolizumab

Entyvio

Generic Name
Vedolizumab
ENTYVIO is indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). moderately to severely active Crohn's disease (CD). ENTYVIO is an integrin receptor antagonist indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). ( 1 ) moderately to severely active Crohn's disease (CD). ( 1 )

Sulfasalazine

Brand Names
Azulfidine, Azulfidine EN-tabs

Sulfasalazine

Brand Names
Azulfidine, Azulfidine EN-tabs
Sulfasalazine delayed release tablets are indicated: a) in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; b) for the prolongation of the remission period between acute attacks of ulcerative colitis; c) in the treatment of patients with rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs (e.g., an insufficient therapeutic response to, or intolerance of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs); and d) in the treatment of pediatric patients with polyarticular-course 1 juvenile rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs. Sulfasalazine delayed release tablets are particularly indicated in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of gastrointestinal intolerance, and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites, e.g., patients experiencing nausea and vomiting with the first few doses of the drug, or patients in whom a reduction in dosage does not alleviate the adverse gastrointestinal effects. In patients with rheumatoid arthritis or juvenile rheumatoid arthritis, rest and physiotherapy as indicated should be continued. Unlike anti-inflammatory drugs, sulfasalazine delayed release tablets do not produce an immediate response. Concurrent treatment with analgesics and/or nonsteroidal anti-inflammatory drugs is recommended at least until the effect of sulfasalazine delayed release tablets is apparent.

Adalimumab

Brand Names
Adalimumab-aacf, Humira

Adalimumab

Brand Names
Adalimumab-aacf, Humira
HUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
Showing 1-5 of 26
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances